SciClone Reaches Agreement to Settle FCPA Derivative Suit

The suit -- a consolidation of four similar plaintiff's actions -- alleged the Foster City, Calif.-based drugmaker made material misstatements about its financial results based on allegedly illegal and improper sales and marketing activities of hepatitis drug Zadaxin in China.

Get unlimited access to all Global Investigations Review content